Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance is a research paper published in Pharmacological Research (2021). On theSindex it has a DataRank of 7.8. It has been cited 792 times, with 200 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.0
From this paper's citation signal
Citation Network Contribution
6.8
From 200 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 200 citers.
NICHD NIH HHS
Grant: R01 HD103638
NCI NIH HHS
Grant: T32 CA009695
NCI NIH HHS
Grant: P30 CA124435
Stanford University
Department of Radiology, Weill Cornell Medical College
National Institutes of Health
FWCI
48.40
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition
Additional file 1 of PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition
Additional file 1 of The short isoform of MS4A7 is a novel player in glioblastoma microenvironment, M2 macrophage polarization, and tumor progression
Additional file 1 of The short isoform of MS4A7 is a novel player in glioblastoma microenvironment, M2 macrophage polarization, and tumor progression
Additional file 1 of Unveiling divergent treatment prognoses in IDHwt-GBM subtypes through multiomics clustering: a swift dual MRI-mRNA model for precise subtype prediction
Additional file 1 of Unveiling divergent treatment prognoses in IDHwt-GBM subtypes through multiomics clustering: a swift dual MRI-mRNA model for precise subtype prediction
Additional file 1 of Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy
Additional file 1 of Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy
Additional file 2 of Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy
Additional file 2 of Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy
Additional file 3 of Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy
Additional file 3 of Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy
Additional file 1 of Radiosynthesis and preclinical evaluation of a 68Ga-labeled tetrahydroisoquinoline-based ligand for PET imaging of C-X-C chemokine receptor type 4 in an animal model of glioblastoma
Additional file 1 of Radiosynthesis and preclinical evaluation of a 68Ga-labeled tetrahydroisoquinoline-based ligand for PET imaging of C-X-C chemokine receptor type 4 in an animal model of glioblastoma
Additional file 1 of Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion
Additional file 1 of Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion
Additional file 2 of Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion
Additional file 2 of Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion
Additional file 2 of PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition
Additional file 2 of PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition